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OBJECTIVES: Patients with Cushing’s disease exhibit wide phenotypic variability in the severity of obesity,
diabetes and hypertension. In the general population, several glucocorticoid receptor genes (NR3C1) and
HSD11B1 polymorphisms are associated with altered glucocorticoid sensitivity and/or metabolism, resulting in
an increased or reduced risk of an adverse metabolic profile. Our aim was to analyze the association of NR3C1
and HSD11B1 gene variants with the severity of some clinical and hormonal features of Cushing’s disease.
METHODS: Sixty-four patients presenting with Cushing’s disease were diagnosed based on adrenocortico-
trophic hormone levels, high-dose dexamethasone suppression tests and/or inferior petrosal sinus sampling and
magnetic resonance imaging. The A3669G, ER22/23EK, N363S BclI-NR3C1 and HSD11B1-rs12086634 variants
were screened.
RESULTS: The BclI, HSD11B1-rs12086634 and A3669G variants were found in 36%, 19.5% and 14% of alleles,
respectively. The N363S and ER22/23EK polymorphisms were identified in heterozygosis once in only two
patients (1.5% of alleles). There were no differences in the weight gain or prevalence of diabetes and
hypertension in the patients carrying the abovementioned alleles compared to the wild-type carriers.
Interestingly, the mean body mass index (BMI) of the BclI carriers was significantly higher than the non-carriers
(34.4¡7 kg/m2 vs. 29.6¡4.7 kg/m2, respectively). None of the polymorphisms were associated with the basal
adrenocorticotrophic hormone, FU levels or F level after dexamethasone suppression testing.
CONCLUSION: Although Cushing’s disease results from increased glucocorticoid secretion, we observed that
interindividual variability in the peripheral glucocorticoid sensitivity, mediated by the glucocorticoid receptor,
could modulate the obesity phenotype.
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& INTRODUCTION
Cushing’s disease (CD) comprises a wide range of clinical
and biochemical features that result from prolonged and
inappropriate glucocorticoid exposure. Elevated glucocorti-
coid levels can result from pituitary adrenocorticotrophic
hormone (ACTH) excess, which is frequently associated
with a pituitary adenoma (1).
The estimated incidence of CD ranges from 0.7 to 2.4 cases
per million individuals per year and typically affects adults
aged between 20 and 50 years of age (2). The clinical
manifestations of CD include weight gain, hypertension,
diabetes, cardiovascular disease and thromboembolic
events, which significantly increase the mortality rate of
CD patients compared to the normal population (3,4). The
cure for CD or its remission frequently reduce mortality
rates but do not completely eliminate cardiovascular risks,
even after the normalization of cortisol (F) secretions (5).
The severity of these comorbidities is at least partially
determined by an interindividual variation in the peripheral
glucocorticoid (GC) sensitivity, which is mediated by
glucocorticoid receptor gene polymorphisms (6).
Several GR polymorphisms have been identified, but only
a few are functionally relevant. The BclI, N363S, ER22/23EK
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and A3669G alleles have been associated with changes in
GC sensitivity as well as with altered cortisol levels (6). In
the general population, the N363S and BclI polymorphisms
exhibit positive associations with the increased prevalence
of abdominal obesity, hypertension and coronary artery
disease (6–8). In addition, because of their increased GC
sensitivity, healthy subjects carrying either the N363S or BclI
polymorphisms exhibit lower serum basal cortisol levels as
well as greater serum cortisol reduction after dexametha-
sone administration (6). In contrast, the ER22/23EK and
A3669G polymorphisms are associated with decreased GC
sensitivity and relative GC resistance. Recent studies have
demonstrated that the presence of the ER22/23EK poly-
morphism is associated with a favorable metabolic profile
and body composition and a smaller decrease in cortisol
levels after a dexamethasone suppression test (DST) (6).
In the context of the associations between GR variants and
an adverse metabolic profile in the general population, two
recent studies have evaluated the effect of these polymorph-
isms on the clinical manifestations of CD (9). The first study
of a cohort comprising 35 patients observed that the BclI
carriers exhibited increased skeletal sensitivity to GC
compared to wild-type carriers (10). The second study, of
a similar sample size, observed that the A3669G carriers
exhibited a lower prevalence of type 2 diabetes compared
with wild-type carriers (9).
However, the interindividual variability in the peripheral
sensitivity to glucocorticoids can be influenced by other
factors in addition to GR activity, including cortisol
regeneration by the 11b-hydroxysteroid dehydrogenases
(11). A polymorphism located in the third intron of the
HSD11B1 gene causes lower transcriptional activity in in
vitro studies (12) and has been associated with lower
intracellular cortisol levels, particularly in adipose and liver
tissues, which are protective features against developing
metabolic syndrome. Consequently, we hypothesized that
the severity of obesity in CD patients could be genetically
influenced by the HSD11B1 polymorphism.
The aim of the present study was to evaluate the
association between the polymorphisms involved in GC
action (GR BclI, N363S, ER22/23EK and A3669G) and
peripheral metabolism (HSD11B1 rs12086634) on the sever-
ity of some clinical and hormonal manifestations in a large
cohort of CD patients who were followed at a single center.
We observed that in addition to manifesting CD, the
severity of obesity in CD patients could be modulated by
genetic factors because the BclI carriers exhibited higher
body mass indices (BMIs) than non-carriers.
& METHODS
Subjects
The study was approved by the Ethical Committee of the
Hospital das Clı´nicas da Faculdade de Medicina da
Universidade de Sao Paulo, and informed consent was
obtained from all the participants.
The study included 64 patients (51 females and 13 males)
with a mean age of 25.2¡5.2 years who underwent first-
time transphenoidal surgery to treat CD between 1989 and
2011 at our institution (Hospital das Clı´nicas da Faculdade
de Medicina da Universidade de Sao Paulo, Endocrinology
Department, Sao Paulo, Brazil). Data regarding the pre-
operative diagnosis (clinical features, laboratory data and
imaging studies) were retrospectively recorded. Genomic
DNA samples were available from all 64 patients.
Diagnosis of CD
CD was diagnosed using the currently accepted standard
criteria (2,13). At least two elevated 24-h urine F excretion
levels and/or failing to suppress serum F during a low-dose
overnight dexamethasone suppression test were used to
establish endogenous hypercortisolemia in all patients.
High-dose dexamethasone suppression and/or a desmo-
pressin test were also performed to evaluate the ACTH and
F and responses. To evaluate the presence of pituitary
adenomas in 2005, computed tomography (CT) was used,
and after that year, magnetic resonance imaging (MRI) was
used. When necessary, inferior petrosal sinus sampling tests
were used to establish the pituitary origin (14).
Tumor size
Tumor size was classified based on preoperative radi-
ologic images (MRI/CT) and intraoperative findings:
microadenoma (tumors #10 mm in the maximal diameter)
or macroadenoma (tumors .10 mm).
Clinical, anthropometric and laboratory
measurements
All of the patients underwent physical examinations to
obtain clinical, hormonal and anthropometric measure-
ments. Obesity was defined as having a BMI.30 kg/m2,
and overweight individuals were characterized by a BMI
between 25 and 30 kg/m2. Patients were defined as having
elevated blood pressure if their blood pressure was .135/
85 mmHg or if they were currently being treated for
hypertension. Elevated glucose levels were defined as
values .110 mg/dL (6.16 mmol/liter).
Plasma F concentrations were measured at 08:00 h and
after a dexamethasone suppression test. One milligram or
8 mg of dexamethasone were given orally at midnight, and
blood was drawn for plasma F measurements the next
morning between 8:00 a.m. and 9:00 a.m. Histopathological
analyses performed after the transphenoidal surgery con-
firmed the presence of an ACTH-producing pituitary
adenoma.
ACTH was measured using RIA and IRMAs. Serum and
urinary cortisol were measured using IRMAs.
GR genotyping
DNA samples from all patients were obtained from
peripheral blood leukocytes using a salting out procedure.
PCR amplification of the glucocorticoid receptor gene
regions was performed using primer sequences and
amplification conditions, as previously described (15,16).
The ER22/23EK allele of GR comprises two linked single-
nucleotide variations that are separated by one base pair in
exon 2. The first substitution at nucleotide position 198 is
silent, changing codon 22 from GAG to GAA, both coding
for a glutamic acid (E). The second mutation changes codon
23 at nucleotide position 200 from AGG to AAG, causing a
change from arginine (R) to lysine (K). The N363S
polymorphism changes codon 363 of exon 2 at nucleotide
position 1220 from AAT to AGT and results in an
asparagine (N) to serine (S) amino acid change. The
A3669G (also called 9b polymorphism) is located in the 39
untranslated region of exon 9b at nucleotide position 3669
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and results in an A to G substitution. These GR alleles were
screened by sequencing.
The HSD11B1 rs12086634 comprises an A insertion at the
83,557 position in intron 3 of the HSD11B1 gene and was
genotyped, as previously described (17). Amplified pro-
ducts were sequenced using the Big Dye Terminator
Sequencing KitTM (Applied Biosystems, Inc., Foster City,
CA, USA) and submitted to capillary electrophoresis using
an ABI PRISM 3100 sequencer (Applied Biosystems, Inc.).
Sequence traces were analyzed using Sequencher (version
4.5, build 1416, Gene Codes Corp., Ann Arbor, Michigan).
The BclI polymorphism of GR results in an intronic C to G
change, 646 nucleotides downstream of exon 2. This
polymorphism was screened using allele-specific PCR, as
previously described (18). The results of the allele-specific
PCR were confirmed by direct sequencing in 20 patients.
Statistical analysis
The comparison of genotypic frequencies between the
different groups of patients and between males and females
was performed using the x2 test. The normal distribution of
all continuous variables was tested, and some variables
were logarithmically transformed. At baseline, independent
t-tests for the independent groups were applied to compare
the continuous variables. The results are reported as the
means¡SD. These analyses were also performed with
adjustments for age and sex by multivariable modeling.
p,0.05 was considered significant.
The Hardy–Weinberg equilibrium for the BclI, A3669G
and HSD11B1 variants was calculated. Considering the
small number of homozygous carriers of GR and HSD11B1
polymorphisms, the homozygous and heterozygous sub-
jects were analyzed as a single group, which was defined as
‘carriers.’
Statistical analysis was performed using the software
SigmaStat, version 3.5 for Windows (Systat Software, Point
Richmond, CA).
& RESULTS
Clinical and hormonal characteristics of CD patients
The clinical and hormonal baseline data of the 64 CD
patients are described in Table 1. The patients exhibited
detectable ACTH levels. Among the patients included in
this study, 47 exhibited corticotropic microadenomas, and
11 exhibited macroadenomas, which were diagnosed with
pituitary MRIs. For six patients, the pituitary lesion was
unidentified, and catheterism of the inferior petrosal sinus
confirmed the pituitary origin of the ACTH secretion.
Obesity was observed in 53% of patients (n = 34, 27
females, seven males), and an overweight phenotype was
observed in 25% of the patients (n = 16, 12 females, four
males). Hypertension was observed in 37.5% of the patients
(n = 24, 18 females, six males), and the fasting plasma
glucose level exceeded 110 mg/dL (6.16 mmol/L) in 28% of
patients (n = 18, 15 females, three males).
The clinical and biochemical features of the patients
exhibiting microadenomas were compared with those of the
patients exhibiting macroadenomas. BMI, weight gain,
blood pressure, fasting glucose levels, basal serum ACTH
and cortisol levels, and serum ACTH and cortisol levels
after DST tests did not differ significantly (p.0.05, data not
shown). However, the patients with microadenomas exhib-
ited higher total urine cortisol levels compared with patients
with macroadenomas (1,203¡794.4 mg/24 h vs. 761.2¡650.7
mg/24 h, respectively. p= 0.01).
Allelic frequencies of the GR and HSD11B1
polymorphisms
The BclI, A3669G and HSD11B1-rs12086634 polymorph-
isms were in Hardy-Weinberg equilibrium, which was not
calculated for the N363S and ER22/23EK polymorphisms
because of the low frequency of the polymorphic genotypes.
Among the GR polymorphisms, the BclI polymorphism
was observed in 36% of the alleles (38 heterozygote and four
homozygote carriers), and the A3669G polymorphism was
observed in 14% of alleles (16 heterozygote carriers and one
homozygote carrier). The N363S and ER22/23EK poly-
morphisms were identified in heterozygosis once in only
two patients (1.5% of alleles). The HSD11B1 rs12086634
allele was observed in 19.5% of alleles (17 heterozygote and
four homozygote carriers).
There was no significant difference in the BclI poly-
morphism frequencies between obese and non-obese CD
patients [n = 26 (76.5%) vs. n = 15 (52.6%), respectively,
p.0.05] nor was there a difference observed between the
patients with and without diabetes [n = 10 (55.5%) vs. n = 30
(73.5%), respectively, p.0.05] and those with and without
hypertension [n = 22 (75.9%) vs. n = 20 (59%), respectively,
p.0.05].
With respect to the A3669G allelic frequencies, no
significant differences were observed in the patients with
and without obesity [n = 9 (26%) vs. n = 10 (33%), respec-
tively, p.0.05], those with and without diabetes [n = 05
(28%) vs. n = 12 (26%), respectively, p.0.05] or those with
and without hypertension [n = 6 (21%) vs. n = 11 (31%),
respectively, p.0.05].
There were no differences in the rs12086634 frequencies
between obese and non-obese patients [n = 12 (35%) vs. n = 9
(30%), respectively, p.0.05], patients with and without
diabetes [n = 07 (39%) vs. n = 14 (30%), respectively, p.0.05]
or with and without hypertension [n = 9 (32%) vs. n = 12
(33%), respectively, p.0.05]. However, a higher frequency
of this polymorphism was observed in the patients with a
macroadenoma compared with the patients with a micro-
adenoma [n = 5 (83.3%) vs. n = 7 (26%), respectively, p= 0.04].
Table 1 - The clinical and hormonal characteristics of 64
CD patients.
Variables Patients
Age at diagnosis, years 31.8¡12.2
BMI, kg/m2 33.2¡6.9
Disease duration, years 4.2¡3.7
Weight gain, kg 24.8¡17.7
Systolic blood pressure, mmHg 140¡20.7
Diastolic blood pressure, mmHg 91.2¡13.9
Fasting glucose, mg/dL 106.9¡42.9
Morning serum cortisol, mg/dl 25.9¡16.5
Basal ACTH, mg/dl 79¡69.7
F after 1 mg DST, mg/dl 15.3¡11.9
F after 8 mg DST, mg/dl 9.7¡8.5
UFC, mg/24 h 1,081¡745
Image
Microadenoma, n˚ (%) 47 (73.4)
Macroadenoma, n˚ (%) 11 (17.2)
Unidentified, n˚ (%) 6 (9.4)
Values are reported as the means¡SD. BMI, Body mass index; DST,
Dexamethasone suppression test; UFC, Urine free cortisol; F, Cortisol.
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The influence of polymorphisms on the clinical and
hormonal characteristics of CD patients
GR polymorphisms
A comparison of the clinical and laboratory data between
carriers and non-carriers of the BclI polymorphism is shown
in Table 2.
BclI carriers exhibited higher BMIs compared to non-
carriers (34.4¡7 kg/m2 and 29.6¡4.7 kg/m2, respectively,
p= 0.01). Although BclI carriers exhibited higher blood
pressure and greater weight gain, these differences did not
reach the level of significance (p.0.05, Table 2).
Significant differences between the BclI carriers and the
non-carriers were not observed with respect to basal
morning cortisol, ACTH, UFC levels or cortisol levels after
1-mg and 8-mg-DSTs (Table 2, p.0.05).
Table 3 shows the clinical and laboratory data of the
A3669G and wild-type carriers. There were no significant
differences in the BMI, blood pressure, fasting glucose or
weight gain between the patients carrying the A3669G and
those carrying the wild-type allele (p.0.05). We also
compared the clinical and laboratory data of seven patients
carrying both BclI and A3669G polymorphisms with those
carrying the wild-type allele, and no significant differences
were detected (data not shown).
There was no difference in the disease duration among
the BclI, A3669G and wild-type carriers.
HSD11B1 gene polymorphism (rs12086634)
The clinical and laboratory data of the HSD11B1
rs12086634 and wild-type carriers are shown in Table 4.
There were no statistically significant differences in the
clinical, laboratory or metabolic data or in the duration of the
disease between patients carrying the HSD11B1 rs12086634
allele and those with the wild-type allele (p.0.05). However,
when considering the co-expression of the HSD11B1
rs12086634 and BclI polymorphisms (seven patients), the
BMI was higher in the group carrying both polymorphisms
compared with the wild type carriers (35.5¡6.7 kg/m2 vs.
30.2¡5.1 kg/m2, respectively, p= 0.04). No differences were
observed in the other parameters analyzed (data not shown,
p.0.05). None of the patients exhibited co-expression of the
HSD11B1 rs12086634 and A3669G polymorphisms.
Table 2 - Comparison of the clinical and hormonal features of CD patients carrying the BclI and wild-type alleles.
Features Wild Type (n= 22) BclI carriers (n = 42) p-value
Age at diagnosis, years 32.2¡10.8 31.5¡12.5 0.773
Disease duration, years 3.6¡3.7 4.5¡3.8 0.185
BMI, kg/m2 29.6¡4.7 34.4¡7 0.012
Weight gain, kg 20.2¡10.1 25¡16.7 0.445
Systolic blood pressure, mmHg 135.3¡15.2 142.5¡22 0.256
Diastolic blood pressure, mmHg 90¡10.9 91.9¡15.4 0.815
Fasting glucose, mg/dL 119¡49.3 98.7¡35.2 0.086
Morning serum cortisol, mg/dl 26.3¡16.7 26.1¡16.7 0.845
Basal ACTH, mg/dl 93.7¡83.7 73.3¡64 0.315
F after 1 mg DST, mg/dL 15.2¡14.2 15.4¡11.2 0.963
F after 8 mg DST, mg/dL 9¡7.6 10.2¡9.3 0.915
UFC, mg/24 h 1,338¡1,143 1,011¡506 0.683
Image
Microadenoma, n˚ (%) 17 (77.3) 30 (71.5) 0.837
Macroadenoma, n˚ (%) 3 (13.6) 8 (19) 0.844
Not identified, n˚ (%) 2 (9.1) 4 (9.5) 0.692
Values are reported as the means¡SD. BMI, Body mass index; DST, Dexamethasone suppression test, DST; Urine free cortisol, UFC; F, Cortisol.
Table 3 - Comparison of the clinical and hormonal features of CD patients carrying the A3669G and wild-type alleles.
Features Wild Type (n= 47) A3669G carriers (n = 17) p-value
Age at diagnosis, years 31.9¡11.1 31.3¡13.7 0.925
Disease duration, years 4.3¡3.8 4¡3.6 0.803
BMI, kg/m2 32.7¡6.1 33.4¡8.2 0.720
Weight gain, kg 23¡15 24.2¡14.6 0.712
Systolic blood pressure, mmHg 142.2¡21.4 135¡19.5 0.209
Diastolic blood pressure, mmHg 91.5¡13.7 90.7¡15.4 0.816
Fasting glucose, mg/dL 104.1¡39.5 108.9¡46.2 0.847
Morning serum cortisol, mg/dl 23¡10.5 32.2¡25.4 0.327
Basal ACTH, mg/dl 81.3¡77.1 73.1¡44 0.708
F after 1 mg DST, mg/dL 15.4¡11.7 15.3¡12.8 0.965
F after 8 mg DST, mg/dL 10.8¡8 8.1¡9.9 0.303
UFC, mg/24 h 1,085¡679 1,169¡970 0.858
Image
Microadenoma, n˚ (%) 33 (70.2) 14 (82.4) 0.515
Macroadenoma, n˚ (%) 10 (21.3) 1 (5.8) 0.286
Not identified, n˚ (%) 4 (8.5) 2 (11.8) 0.9
Values are reported as the means¡SD. BMI, Body mass index; DST, Dexamethasone suppression test; UFC, Urine free cortisol; F, Cortisol.
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& DISCUSSION
It is widely recognized that CD patients are predisposed
to developing obesity and other metabolic abnormalities,
including visceral obesity, hypertension and insulin resis-
tance (19), which increases their cardiovascular risk and
contributes to the high mortality rates associated with this
disease (20). These metabolic abnormalities have been
associated with the effects of long-term GC overexposure,
which inhibits the immune and pro-inflammatory responses
by suppressing the synthesis of cytokines and inflammatory
mediators (21). In CD patients, the increased cardiovascular
risk is not only observed during the active phase of the
disease but may be observed for a long time after the disease
remission.
Although chronic GC exposure is associated with a worse
metabolic profile (13), the frequencies of these comorbidities
differ among CD patients and are not related to the disease
duration. This lack of correlation suggests the presence of
other variables that may modulate the clinical manifestations.
Recently, in a cohort comprising 30 patients, tumor size
was reported to affect the clinical manifestation of CD
patients; the patients with microadenomas exhibited higher
blood pressure compared to those with macroadenomas
(22). In our series, we did not observe differences between
the metabolic profiles of patients with micro- and macro-
adenomas nor did we observe differences in the basal serum
ACTH and cortisol levels, even after DST. In contrast to the
results previously described in two series comprising 18 and
20 macroadenomas (23,24), we observed higher total urine
cortisol levels among the patients with microadenomas
compared with those with macroadenomas. Most likely our
discordant results could be related to the sample size effect.
In addition to the effect of tumor size, the peripheral GC
sensitivity can play an important role in the modulatory
effect of cortisol exposure (26). Several studies have
demonstrated the influence of GR polymorphisms on
glucocorticoid sensitivity and peripheral action (6,27). In
the general population, the BclI polymorphism has been
associated with enhanced GC sensitivity and consequently
with a worse metabolic profile, including high blood
pressure, waist to hip circumference, BMI, hyperinsuline-
mia, impaired glucose metabolism and dyslipidemia (9,28).
In our study, we observed a positive association between
the BclI carrier status and an elevated BMI, which is in line
with previous studies that found a significant association
between this polymorphism and obesity in the general
population (29–32). A recent study in a series of 52 patients
with Cushing’s syndrome did not identify any influence of
BclI polymorphisms on the patients’ metabolic profiles (9).
Note that this latter study enrolled patients with different
Cushing’s etiologies: 38 had CD, and 14 patients exhibited
adrenal Cushing’s syndrome (ACS).
The influence of the BclI polymorphism in the prevalence
of metabolic complications has also been demonstrated in
patients with adrenal incidentalomas without evidence of
overt hypercortisolism. An increased frequency of arterial
hypertension was observed in homozygous BclI patients
(33). Although in our cohort the BclI carriers tended to
develop high blood pressure, this tendency did not reach
the level of significance. However, in our study, only four
patients were BclI homozygous carriers.
The A3669G polymorphism of the GR gene has been
related to the increased expression and stability of the GR-b
isoform in vivo, which does not bind efficiently to GCs or
activate GC-response genes. In addition, the GR-b isoform
acts as a dominant negative inhibitor of the active GR-a
isoform, leading to a relative GC resistance (6). This
polymorphism has been associated with increased levels
of inflammatory parameters and, consequently, with an
increased risk of myocardial infarction and cardiovascular
heart disease in homozygous carriers (34), but an association
between the A3669G polymorphism and a favorable lipid
profile in men and a decreased waist-hip ratio in women
were also implicated (35). In a series of 52 patients with
Cushing’s syndrome, this variant was observed to act as a
protective factor against the developing diabetes (9). In
contrast to this study, we did not observe differences in the
clinical, hormonal or anthropometric features between the
A3669G carriers and non-carriers in our cohort.
In humans, 11b-HSD1 expression has been observed to
increase in the adipose tissue of obese patients (36), and the
role of HSD11B1 gene polymorphisms in the prevalence of
metabolic syndrome has been explored (17,37,38). A frequent
polymorphism, rs12086634, accounts for decreased 11b-
HSD1 transcriptional activity in vitro (12) and suppressed
Table 4 - Comparison of the clinical and hormonal features of CD patients carrying the HSD11B1 rs12086634 and wild-
type alleles.
Features Wild Type (n =43) rs12086634 carriers (n = 21) p-value
Age at diagnosis, years 30.9¡12.8 33¡9.2 0.532
Disease duration, years 4.1¡3.7 4.5¡4 0.770
BMI, kg/m2 32.3¡7 33¡6.7 0.715
Weight gain, kg 25.9¡16.1 18¡10.1 0.100
Systolic blood pressure, mmHg 139.4¡20.6 141.8¡22.1 0.679
Diastolic blood pressure, mmHg 90.3¡14 93.2¡14 0.496
Fasting glucose, mg/dL 103.5¡41.4 110.1¡41.4 0.410
Morning serum cortisol, mg/dl 26.8¡17.8 24.7¡13.4 0.663
Basal ACTH, mg/dl 72.7¡4.4 93.8¡107.7 0.723
1 mg DST, mg/dL 14.3¡11 17.6¡14 0.419
8 mg DST, mg/dL 8¡8.4 10.7¡8.4 0.546
UFC, mg/24 h 1,081¡684 1,167¡920 0.768
Image
Microadenoma, n˚ (%) 34 (79.1) 13 (61.9) 0.246
Macroadenoma, n˚ (%) 4 (9.3) 7 (33.3) 0.041
Not identified, n˚ (%) 5 (11.6) 1 (4.7) 0.687
Values are reported as the means¡SD. BMI, Body mass index; DST, Dexamethasone suppression test; UFC, Urine free cortisol; F, Cortisol.
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intracellular cortisol levels; it acts as a protective factor
against the features of the metabolic syndrome.
To the best of our knowledge, this study is the first to
evaluate the role that the HSD11B1 gene polymorphism
(rs12086634) plays in the clinical, anthropometric and
hormonal profiles of CD patients. Nevertheless, contrary
to our expectations, we did not find any association among
the HSD11B1 genotype, clinical and hormonal profiles of
CD patients (Table 4). However, only four patients were
homozygous for this variant. Interestingly, the frequency of
this polymorphism was significantly higher in the patients
with macroadenomas compared with those with micro-
adenomas (Table 4). Given that macroadenomas are often
associated with higher serum ACTH levels compared with
microadenomas (24), we speculated that this result could be
explained by the fact that the HSD11B1 rs12086634 reduces
11b-HSD1 transcriptional activity, consequently impairing
the cortisol regeneration in peripheral tissues and resulting
in the compensatory activation of ACTH secretion.
Our study has some limitations. First, our sample size
was limited because we tried to select a homogenous cohort
and only enrolled patients with pituitary CD origins.
Second, this study was retrospective, and glucose tolerance
tests were not available for several patients at that time.
Therefore, the role of GR polymorphisms in diabetes
frequency could not be evaluated precisely.
In conclusion, this study is the first to demonstrate an
association between the BclI polymorphism and increased
BMI values in CD patients. This study is also the first to
demonstrate the possible influence of the HSD11B1-
rs12086634 polymorphism in tumor size. These findings
may provide new insights into the genetic factors that
influence the phenotypic variability of CD patients.
Translating these findings into clinical practice could help
manage this patient group by identifying subgroups of
patients who are at-risk for developing higher BMIs and
associated comorbidities, such as hypertension and insulin
resistance; these patients would benefit the most from
personalized treatment.
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